For Patients

PROKERA®

PROKERA is a combination medical device used by eye doctors around the world for anti-inflammation, anti-scarring and promoting healing of damaged eye surfaces. It contains the only FDA-cleared cryopreserved amniotic membrane — supports the corneal-healing process without harmful side effects.1,2,3.

Amniotic membrane is part of the placenta and is the tissue closest to the baby throughout development in the womb. Amniotic membrane protects the baby from any harm and has natural biologic actions which help the baby develop. The tissue has biological properties that aid in ocular surface repair.

The amniotic membrane tissue in PROKERA has natural therapeutic actions that help damaged eye surfaces heal. Eyes treated with PROKERA have less scarring and less inflammation. The amniotic membrane in PROKERA is thin and clear like the tissue on the surface of your eye and protects your eye’s damaged tissue while inserted.

PROKERA is used by eye doctors to treat eye diseases such as keratitis, corneal scars, chemical burns, corneal defects, partial limbal stem cell deficiency and many other ocular surface diseases with inflammation.

PROKERA is provided by a tissue bank regulated by the FDA. The tissue has passed many quality control tests before it is provided to your doctor. Ask your doctor if you are concerned about the risks involved with using a human tissue.

Patient Resources

Here are additional resources to learn more about PROKERA:

  • PROKERA Patient Brochure - DOWNLOAD
  • PROKERA Patient Brochure (Spanish) - DOWNLOAD
  • PROKERA What To Expect Patient Guide - DOWNLOAD
  • PROKERA What To Expect Patient Guide (Spanish) - DOWNLOAD

AmnioGraft®

AmnioGraft is the only amniotic membrane tissue that has been recognized by the FDA for its unique anti-inflammatory, anti-scarring, and anti-angiogenic properties. This tissue is used by eye surgeons around the world to protect, repair, and promote regenerative healing of damaged eye surfaces.

Amniotic membrane is part of the placenta. It is the tissue closest to the baby throughout development in the womb. The biological properties of amniotic membrane protects the baby from any harm and its natural therapeutic actions helps the baby develop.

The placentas used to prepare AmnioGraft are donated by consenting mothers after cesarean section births. Mothers that donate are fully informed, have healthy lifestyles, and are tested against infectious diseases prior to donation.

Patient Resources

Download additional information below:

  • AmnioGraft Patient Guide - DOWNLOAD
  • AmnioGraft Mechanical Dry Eye Patient Guide - DOWNLOAD
  • AmnioGraft Pterygium Patient Guide - DOWNLOAD
  • AmnioGraft Pterygium Patient Guide (Spanish) - DOWNLOAD

AmnioGraft: “The Gold Standard” for Ocular Surface Reconstruction

AmnioGraft has natural properties that help damaged eye surfaces heal faster. Eyes treated with AmnioGraft have quicker healing, less scarring, and less inflammation. AmnioGraft is thin and clear like the tissue on the surface of your eye. It is used to replace damaged tissue on the surface of your eye and provide protection after surgery.

AmnioGraft is used to help manage symptoms of eye diseases such as corneal defects, partial stem cell deficiency, chemical burns, conjunctivochalasis, pterygium, symblepharon and many other ocular surface conditions.

AmnioGraft is a safe, effective product provided by FDA-regulated tissue bank. The tissue has passed many quality control tests before it is provided to your doctor. AmnioGraft has never been associated with any serious adverse events in the last 20 years of widespread clinical use. Ask your doctor if you are concerned about the risk involved with using human tissue.

AmnioGuard®

Bio-Tissue® also develops AmnioGuard®, a biologic glaucoma shunt graft that is used by glaucoma specialists to cover a wide variety of glaucoma drainage devices.

References:
1 Desai NR. A comparison of cryopreserved amniotic membrane and bandage contact lens in their ability to provide high-quality healing after superficial keractectomy. Rev Ophthalmol. September 2014:1-6
2 Pachigolla G, Prasher P, Di Pascuale MA, et al. Evaluation of the role of PROKERA in the management of ocular surface and orbital disorders. Eye Contact Lens. 2009;35(4):172-175.
3 Morkin MI, Hamrah P. Efficacy of self-retained cryopreserved amnioticmembrane for treatment of neuropathic corneal pain. Ocul Surf. 2018;16(1):132-138.